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Background
Colorectal cancer (CRC) is the third leading cancer killer
in the United States, affecting both men and women. Stan-
dard treatment for stage II colon cancer is surgical
removal of the cancer and an area surrounding the cancer.
Adjuvant chemotherapy may also be given as a precaution
against cancer recurrence, usually recommended to high-
risk patients. Recent studies have shown that for stage II
patients, adjuvant therapy does not increase overall survi-
val, but there is a significant increase in progression-free
survival after therapy [1]. Therefore, it is important to
identify a subgroup of patients with the highest risk of
relapse who can potentially benefit from adjuvant
chemotherapy. The informatics team at Georgetown
University has generated and analyzed multi-omics profil-
ing datasets in stage II CRC patients with or without
relapse to identify molecular signatures in CRC that may
serve both as prognostic markers of recurrence, and also
allow for identification of the subgroup of patients who
might benefit from adjuvant chemotherapy.
Methods and Results
Mass spectrum data from serum and urine samples of
40 CRC patients (20 relapse and 20 relapse-free sam-
ples) were collected and pre-processed using a standard
pre-processing pipeline. Statistical group comparison
was performed using t-test (Bio-conductor). A total of
77 differential metabolites in serum and 47 in urine
were identified. Nearly 60% of differential metabolites in
both urine and serum were identified using the in-house
developed Metabolomics - Data Analysis and Annota-
tion Pipeline (M-DAAP). Enrichment analysis revealed
top enriched pathways, including ‘Nicotinate and Nicoti-
namide Metabolism’ (P = 0.007) in urine and ‘Methionine
Metabolism’ (P = 0.002) in serum. A comprehensive cata-
logue of genomic alterations in the coding regions of
40 tumor samples was also generated by whole-exome
sequencing to decipher the mutational landscape asso-
ciated with CRC relapse. Enrichment analysis of the statis-
tically significant genes from a gene-based association test
revealed several pro-inflammatory and chromatin remo-
deling pathways, including ‘BradykininR® STAT3 signal-
ing’ (P = 0.005); ‘INO80 Chromatin Remodeling’
(P = 0.013); and ‘TNFR ® AP-1/ ATF/TP53 signaling’
(P = 0.03).
Conclusions
Preliminary exome data analysis revealed proinflammatory
signaling as the most significant pathway. Bradykinin (BK)
is a potent pro-inflammatory mediator and, together with
TNF-a (another pro-inflammatory cytokine implicated in
CRC), has been observed in colonic myofibroblasts, lead-
ing to enhanced signaling of several downstream kinases
involved in oxidative stress, tumor proliferation and
metastasis [2]. Urinary metabolites revealed Nicotinate
and Nicotinamide Metabolism as the top enriched path-
way. Genes in this pathway have been shown to be differ-
entially expressed in colon cancer cells and are also closely
related to oxidative stress and inflammatory response [3]
and thus support its potential biological role in colon
cancer etiology.
Acknowledgements
The authors thank the Lombardi Shared Resources for generating the
metabolomics datasets. They also thank Dr Louis Weiner and Dr Steve Byers
for their support. This effort was partly funded by NCI’s in silico research
centers for excellence contract.Innovation Center for Biomedical Informatics, Georgetown University Medical
Center, Washington DC, 20007, USA
Gauba et al. BMC Proceedings 2012, 6(Suppl 6):P41
http://www.biomedcentral.com/1753-6561/6/S6/P41
© 2012 Gauba et al; licensee BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative Commons
Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in
any medium, provided the original work is properly cited.
Published: 1 October 2012
References
1. Figueredo A, Coombes ME, Mukherjee S: Adjuvant therapy for completely
resected stage II colon cancer. Cochrane Database Syst Rev 2008, 3:
CD005390.
2. Yoo J, Rodriguez Perez CE, Nie W, Sinnett-Smith J, Rozengurt E: Protein
kinase D1 mediates synergistic MMP-3 expression induced by TNF-α and
bradykinin in human colonic myofibroblasts. Biochem Biophys Res
Commun 2011, 413:30-5.
3. Garten A, Petzold S, Körner A, Imai S, Kiess W: Nampt linking NAD biology,
metabolism and cancer. Trends Endocrinol Metab 2009, 20:130-8.
doi:10.1186/1753-6561-6-S6-P41
Cite this article as: Gauba et al.: Metabolomic and exome sequence
analysis reveal novel molecular signatures associated with colorectal
cancer relapse. BMC Proceedings 2012 6(Suppl 6):P41.
Submit your next manuscript to BioMed Central
and take full advantage of: 
• Convenient online submission
• Thorough peer review
• No space constraints or color figure charges
• Immediate publication on acceptance
• Inclusion in PubMed, CAS, Scopus and Google Scholar
• Research which is freely available for redistribution
Submit your manuscript at 
www.biomedcentral.com/submit
Gauba et al. BMC Proceedings 2012, 6(Suppl 6):P41
http://www.biomedcentral.com/1753-6561/6/S6/P41
Page 2 of 2
